Treatment of extensive-stage small cell lung carcinoma: Current status and future prospects

European Respiratory Journal

Volumn 35, Issue 1, 2010, Pages 202-215

  Demedts, I K ^a   Vermaelen, K Y ^a   Van Meerbeeck, J P ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Chemotherapy; Extensive disease; Radiotherapy; Small cell lung cancer; Treatment

Indexed keywords

ALKYLATING AGENT; AMRUBICIN; ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BELOTECAN; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DALTEPARIN; DOXORUBICIN; ENOXAPARIN; EPIRUBICIN; ETOPOSIDE; FOLIC ACID ANTAGONIST; IFOSFAMIDE; IRINOTECAN; PACLITAXEL; PEMETREXED; PICOPLATIN; PLATINUM DERIVATIVE; PRAVASTATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SIMVASTATIN; TAXANE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ADD ON THERAPY; ANEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CROSS RESISTANCE; DIARRHEA; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LUNG SMALL CELL CANCER; META ANALYSIS; MYELOABLATIVE CONDITIONING; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FORECASTING; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; SMALL CELL LUNG CARCINOMA;

EID: 75149169449     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00105009     Document Type: Review

References (128)

1. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973; 4: 31-42.
2. Stahel R, Ginsberg R, Havemann K, et al. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 1989; 5: 119-126.
3. Shepherd FA, Crowley J, Van Houtte P, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007; 2: 1067-1077.
4. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007; 357: 664-672.
5. Kato Y, Ferguson TB, Bennett DE, et al. Oat cell carcinoma of the lung. A review of 138 cases. Cancer 1969; 23: 517-524.
6. Agra Y, Pelayo M, Sacristan M, et al. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev 2003; 4: CD001990.
7. Giordano KF, Jatoi A, Adjei AA, et al. Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution. Lung Cancer 2005; 49: 209-215.
8. Evans WK, Shepherd FA, Feld R, et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985; 3: 1471-1477.
9. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10: 282-291.
10. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000; 83: 8-15.
11. Mascaux C, Paesmans M, Berghmans T, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000; 30: 23-36.
12. Amarasena IU, Walters JA, Wood-Baker R, et al. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev 2008; 4: CD006849.
13. Sundstrøm S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002; 20: 4665-4672.
14. Kosmidis PA, Samantas E, Fountzilas G, et al. Cisplatin/ etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol 1994; 21: Suppl. 6, 23-30.
15. Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer: A Hellenic Co-operative Oncology Group study. Ann Oncol 1994; 5: 601-607.
16. Souhami RL, Spiro SG, Rudd RM, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997; 89: 577-580.
17. Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Lancet 1996; 348: 563-566.
18. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346: 85-91.
19. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006; 24: 2038-2043.
20. Hermes A, Bergman B, Bremnes R, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008; 26: 4261-4267.
21. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009; 27: 2530-2535.
22. Artal-Cortes A, Gomez-Codina J, Gonzalez-Larriba JL, et al. Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer. Clin Lung Cancer 2004; 6: 175-183.
23. Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 2006; 24: 2044-2051.
24. Heigener DF, Freitag L, Eschbach C, et al. Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED-SCLC): final results of a randomised phase III trial. J Clin Oncol 2008; 26: Suppl. 15, 7513.
25. Socinski MA, Weissman C, Hart LL, et al. randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol 2006; 24: 4840-4847.
26. Niell HB, Herndon JE 2nd, Miller AA, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005; 23: 3752-3759.
27. Loehrer PJ Sr, Ansari R, Gonin R, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995; 13: 2594-2599.
28. Pujol JL, Daures JP, Riviere A, et al. Etoposide plus cisplatin with or without the combination of 4′-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001; 93: 300-308.
29. de Jong WK, Groen HJM, Koolen MGJ, et al. Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer. Eur J Cancer 2007; 43: 2345-2350.
30. Baka S, Califano R, Ferraldeschi R, et al. Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer 2008; 99: 442-447.
31. Torti FM, Bristow MM, Lum BL, et al. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 1986; 46: 3722-3727.
32. Ohe Y, Negoro S, Matsui K, et al. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensivestage small-cell lung cancer. Ann Oncol 2005; 16: 430-436.
33. Yana T, Negoro S, Takada M, et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 2007; 25: 253-258.
34. AMR PH GL 2007 CL 001 Phase 3 Trial in Patients with Small Cell Lung Cancer after Failure of First-Line Chemotherapy. www.clinicaltrials.gov/ct2/ show/NCT00547651 Date last updated: September 25, 2009. Date last accessed: October 9, 2009.
35. Phase 3 Study of Amrubicin with Cisplatin versus Etoposide-Cisplatin for Extensive Disease Small Cell Lung Cancer. www.clinicaltrials.gov/ct2/show/NCT00660504 Date last updated: August 19, 2009. Date last accessed: October 9, 2009.
36. Innocenti F, Kroetz DL, Schuetz E, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009; 27: 2604-2614.
37. Quoix E, Breton J-L, Gervais R, et al. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer. Lung Cancer 2005; 49: 253-261.
38. Lee DH, Kim S-W, Suh C, et al. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Ann Oncol 2008; 19: 123-127.
39. Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient (COMBAT). www.clinicaltrials.gov/ct2/show/NCT00826644 Date last updated: January 21, 2009. Date last accessed: May 14, 2009.
40. Socinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC): interim results. J Clin Oncol 2008; 26: 400S.
41. Smit EF, Fokkema E, Biesma B, et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 1998; 77: 347-351.
42. Mavroudis D, Papadakis E, Veslemes M, et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 2001; 12: 463-470.
43. Klasa R, Murray N, Coldman A. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 1991; 9: 499-508.
44. Klasa R, Murray N, Coldman A. Dose intensity (DI) analysis of chemotherapy in small cell carcinoma of the lung (SCCL). Proc Am Soc Clin Oncol 1987; 6: 173.
45. Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage smallcell lung cancer. J Clin Oncol 1994; 12: 2022-2034.
46. Pujol JL, Douillard JY, Riviere A, et al. Dose-intensity of a fourdrug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. J Clin Oncol 1997; 15: 2082-2089.
47. Ardizzoni A, Tjan-Heijnen VC, Postmus PE, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol 2002; 20: 3947-3955.
48. Berghmans T, Paesmans M, Lafitte JJ, et al. Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer 2002; 37: 115-123.
49. Lorigan P, Woll PJ, O'Brien ME, et al. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst 2005; 97: 666-674.
50. Leyvraz S, Pampallona S, Martinelli G, et al. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. J Natl Cancer Inst 2008; 100: 533-541.
51. Giaccone G, Dalesio O,McVie GJ, et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J ClinOncol 1993; 11: 1230-1240.
52. Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 2114-2122.
53. Sculier JP, Berghmans T, Castaigne C, et al. Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer 1998; 19: 141-151.
54. Bozcuk H, Artac M, Ozdogan M, et al. Does maintenance/ consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials. Cancer 2005; 104: 2650-2657.
55. Rinaldi M, Belvedere O, Cauchi C, et al. Maintenance chemotherapy in non-small cell lung cancer. Ann Oncol 2006; 17: Suppl. 2, ii67-ii70.
56. Postmus PE, Scagliotti G, Groen HJ, et al. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC phase III trial. Eur J Cancer 1996; 32A: 1498-1503.
57. Akl EA, Kamath G, Kim SY, et al. Oral anticoagulation for prolonging survival in patients with cancer. Cochrane Database Syst Rev 2007; 2: CD006466.
58. Akl EA, van Doormaal FF, Barba M, et al. Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. J Exp Clin Cancer Res 2008; 27: 4.
59. A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer (RASTEN). www.clinicaltrials.gov/ct2/show/NCT00717938 Date last updated: September 16, 2009. Date last accessed: October 9, 2009.
60. Dalteparin in Preventing Blood Clots in Patients with Lung Cancer. www.clinicaltrials.gov/ct2/show/NCT00519805 Date last updated: October 6, 2009. Date last accessed: October 9, 2009.
61. Khanzada UK, Pardo OE, Meier C, et al. Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. Oncogene 2006; 25: 877-887.
62. Kip1 and PI3 kinase. J Am Soc Nephrol 1999; 10: 1880-1890.
63. Ravi RK, Weber E, McMahon M, et al. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest 1998; 101: 153-159.
64. Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy with or Without Pravastatin in Treating Patients with Small Cell Lung Cancer. www.clinicaltrials.gov/ct2/show/NCT00433498 Date last updated: February 6, 2009. Date last accessed: May 14, 2009.
65. Bentzion D, Lipatov O, Polyakov I, et al. A phase II study of picoplatin (pico) as second-line therapy for patients (pts) with small cell lung cancer (SCLC) who have resistant or refractory disease or have relapsed within 180 days of completing first-line, platinum (plat)-containing chemotherapy. J Clin Oncol 2007; 25: Suppl. 18, 7722.
66. Treat J, Schiller J, Quoix E, et al. ZD0473 treatment in lung cancer: an overview of the clinical trial results. Eur J Cancer 2002; 38: Suppl. 8, S13-S18.
67. Study of Picoplatin Efficacy After Relapse (SPEAR). www.clinicaltrials. gov/ct2/show/NCT00465491 Date last updated: April 13, 2009. Date last accessed: May 14, 2009.
68. A Phase I/II Study of Carboplatin and Etoposide with or without Obatoclax in Extensive-Stage Small Cell Lung Cancer (ES-SCLC). www.clinicaltrials.gov/ ct2/show/NCT00682981 Date last updated: September 14, 2009. Date last accessed: October 9, 2009.
69. Obatoclax Mesylate and Topotecan in Treating Patients with Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors. www.clinicaltrials. gov/ct2/show/NCT00521144 Date last updated: July 7, 2009. Date last accessed: October 9, 2009.
70. Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer. www.clinicaltrials.gov/ct2/show/NCT00740636 Date last updated: September 18, 2009. Date last accessed: October 9, 2009.
71. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17: 658-667.
72. Rosti G, Bevilacqua G, Bidoli P, et al. Small cell lung cancer. Ann Oncol 2006; 17: Suppl. 2, ii5-ii10.
73. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24: 5441-5447.
74. Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007; 25: 2086-2092.
75. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001; 19: 1743-1749.
76. Hoang T, Kim K, Jaslowski A, et al. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung Cancer 2003; 42: 97-102.
77. van der Lee I, Smit EF, van Putten JW, et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol 2001; 12: 557-561.
78. Masters GA, Declerck L, Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group trial 1597. J Clin Oncol 2003; 21: 1550-1555.
79. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10: 1225-1229.
80. Joos G, Schallier D, Pinson P, et al. Paclitaxel (PTX) as second line treatment in patients (pts) with small cell lung cancer (SCLC) refractory to carboplatin - etoposide: a multicenter phase II study. J Clin Oncol 2004; 22: Suppl. 14, 7211.
81. Furuse K, Kubota K, Kawahara M, et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Oncology 1996; 53: 169-172.
82. Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C, et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer 1993; 29A: 1720-1722.
83. Hanna NH, Ansari R, Bhatia S, et al. Pemetrexed in patients (pts) with relapsed small cell lung cancer (SCLC): a phase II study from the Hoosier Oncology Group. J Clin Oncol 2006; 24: Suppl. 18, 7063.
84. Gronberg BH, Bremnes RM, Aasebo U, et al. A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer 2009; 63: 88-93.
85. Socinski MA, Raju RN, Neubauer M, et al. Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial. J Thorac Oncol 2008; 3: 1308-1316.
86. Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group study 0301. J Clin Oncol 2006; 24: 5448-5453.
87. Kato T, Nokihara H, Ohe Y, et al. Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC). J Clin Oncol 2006; 24: Suppl. 18, 7061.
88. Kudoh S, Yoshimura N, Kimura T, et al. A phase II trial of amrubicin (AMR) for recurrent or refractory small cell lung cancer (SCLC). J Clin Oncol 2006; 24: Suppl. 18, 17053.
89. Ettinger DS, Jotte RM, Gupta V, et al. A phase II trial of singleagent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) that is refractory or progressive within 90 days of completion of first-line platinum-based chemotherapy. J Clin Oncol 2008; 26: Suppl. 15, 8041.
90. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group trial 0402. J Clin Oncol 2008; 26: 5401-5406.
91. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987; 316: 912-918.
92. Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol 1999; 17: 2092-2099.
93. Nederlands Trial RegisterRandomised Trial on Chest Irradiation in Extensive Disease Small Cell Lung Cancer. www.trialregister.nl/trialreg/admin/ rctview.asp?TC51527 Date last updated: January 21, 2009. Date last accessed: May 14, 2009.
94. Slotman BJ, Mauer ME, Bottomley A, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol 2009; 27: 78-84.
95. Moore AM, Einhorn LH, Estes D, et al. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 2006; 52: 93-97.
96. Dy GK, Miller AA, Mandrekar SJ, et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005; 16: 1811-1816.
97. Krug LM, Crapanzano JP, Azzoli CG, et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 2005; 103: 2128-2131.
98. Johnson BE, Fischer T, Fischer B, et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003; 9: 5880-5887.
99. Schneider BJ, Gadgeel S, Ramnath N, et al. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-kit positive extensive-stage small cell lung cancer (ES SCLC). J Clin Oncol 2006; 24: Suppl. 18, 17089.
100. Spigel DR, Hainsworth JD, Simons L, et al. Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. J Thorac Oncol 2007; 2: 854-861.
101. Sandler A, Szwaric S, Dowlati A, et al. A phase II study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previously untreated extensive stage small cell lung cancer (SCLC) (E3501): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2007; 25: Suppl. 18, 7564.
102. Ready N, Dudek AZ, Wang XF, et al. CALGB 30306: a phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC). J Clin Oncol 2007; 25: Suppl. 18, 7563.
103. Jalal SI, Bhatia S, Einhorn LH, et al. Paclitaxel (P) plus bevacizumab (B) in patients (pts) with chemosensitive relapsed small cell lung cancer (SCLC): a safety, feasibility and efficacy trial from the Hoosier Oncology Group. J Clin Oncol 2008; 26: Suppl. 15, 19013.
104. Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group study BR.20. J Clin Oncol 2007; 25: 4278-4284.
105. Gitlitz BJ, Glisson BS, Moon J, et al. Sorafenib in patients with platinum (plat) treated extensive stage small cell lung cancer (ESCLC): a SWOG (S0435) phase II trial. J Clin Oncol 2008; 26: Suppl. 15, 8039.
106. Pujol JL, Breton JL, Gervais R, et al. Phase III double-blind, placebocontrolled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol 2007; 25: 3945-3951.
107. Lee SM, James L, Buchler T, et al. Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer. Lung Cancer 2008; 59: 364-368.
108. Ramalingam SS, Mack PC, Vokes EE, et al. Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): a California Consortium phase II study (NCI # 7097). J Clin Oncol 2008; 26: Suppl. 15, 8078.
109. Haeder M, Rotsch M, Bepler G, et al. Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res 1988; 48: 1132-1136.
110. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
111. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645-4655.
112. Dowlati A, Subbiah S, Cooney M, et al. Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. Lung Cancer 2007; 56: 377-381.
113. Lee SM, Woll PJ, James LE, et al. A phase III randomised, double blind, placebo controlled trial of etoposide/carboplatin with or without thalidomide in advanced small cell lung cancer. J Thorac Oncol 2007; 2: Suppl. 4, S306.
114. Pandya KJ, Dahlberg S, Hidalgo M, et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2007; 2: 1036-1041.
115. Micke P, Basrai M, Faldum A, et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res 2003; 9: 188-194.
116. Krystal GW, Honsawek S, Litz J, et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000; 6: 3319-3326.
117. Michael M, Babic B, Khokha R, et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 1999; 17: 1802-1808.
118. Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with smallcell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20: 4434-4439.
119. Rigas JR, Denham CA, Rinaldi D, et al. Adjuvant targeted therapy in unresectable lung cancer: the results of two randomized placebo-controlled trials of BAY 12-9566, a matrix metalloproteinase inhibitor (MMPI). Lung Cancer 2003; 41: Suppl. 2, S34-S34.
120. Giaccone G, Debruyne C, Felip E, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 2005; 23: 6854-6864.
121. Ziegler A, Luedke GH, Fabbro D, et al. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 1997; 89: 1027-1036.
122. Zangemeister-Wittke U, Schenker T, Luedke GH, et al. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 1998; 78: 1035-1042.
123. Rudin CM, Salgia R, Wang X, et al. Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008; 26: 870-876.
124. Simon GR, Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132: Suppl. 3, 324S-339S.
125. Sorensen M, Felip E. Small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19: Suppl. 2, ii41-ii42.
126. National Collaborating Centre for Acute CareLung Cancer. The Diagnosis and Treatment of Lung Cancer. London, National Institute for Clinical Excellence, 2005. www.nice.org.uk/nicemedia/pdf/CG024niceguideline.pdf. Date last updated: February 2005. Date last accessed: May 14, 2009.
127. National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology. Small Cell lung cancer. www.nccn.org/professionals/physician-gls/PDF/ sclc.pdf Date last accessed: May 14, 2009.
128. Carboplatin and Etoposide in Combination with Vorinostat for Patients with Extensive Stage Small Cell Lung Cancer. www.clinicaltrials.gov/ct2/show/ NCT00702962 Date last updated: February 3, 2009. Date last accessed: May 14, 2009.